Rodman & Renshaw started coverage on shares of Omeros (NASDAQ:OMER - Free Report) in a research report released on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $9.00 price target on the biopharmaceutical company's stock.
Separately, StockNews.com downgraded Omeros from a "hold" rating to a "sell" rating in a report on Tuesday.
View Our Latest Research Report on Omeros
Omeros Trading Up 43.0 %
Shares of Omeros stock traded up $1.80 during trading hours on Thursday, hitting $5.99. 12,127,970 shares of the company were exchanged, compared to its average volume of 449,566. The stock has a market capitalization of $347.12 million, a price-to-earnings ratio of -2.23 and a beta of 1.47. The business has a 50-day moving average of $4.02 and a 200-day moving average of $4.05. Omeros has a 1 year low of $1.38 and a 1 year high of $7.51.
Institutional Trading of Omeros
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. SPC Financial Inc. acquired a new stake in Omeros in the 3rd quarter valued at about $77,000. SG Americas Securities LLC bought a new position in Omeros in the third quarter valued at approximately $80,000. Oppenheimer & Co. Inc. bought a new stake in shares of Omeros in the first quarter worth about $85,000. Finally, Comerica Bank increased its stake in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 5,000 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.
Omeros Company Profile
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
